Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Breast Cancer
- HER2-negative Breast Cancer
- ER+ Breast Cancer
- Advanced Breast Cancer
- Metastatic Breast Cancer With Bone Involvement
- Bone Metastases in Subjects With Advanced Breast Cancer
- ER-Positive HER2-Negative Breast Cancer
- Estrogen Receptor-positive Breast Cancer
- Hormone-sensitive Metastatic Breast Cancer
- Hormone-Sensitive Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- Any age
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- RayzeBio, Inc.
- Last updated on ClinicalTrials.gov
- November 12, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Research Facility · Santa Monica, CA
Colorado · 1
- Research Facility · Longmont, CO
Nebraska · 1
- Research Facility · Omaha, NE
Washington · 1
- Research Facility · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.